Program
RO7823653
A development code.
Its studies are mostly in Macular Edema, led by Hoffmann-La Roche.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 11 open or running | phase 1since Feb 16, 2026 | Feb 16, 2026 | Nov 17, 2028phase 1 · NCT07425522 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 16, 2026First study: phase 1 study in Diabetic Macular EdemaFirst studyNCT07425522 · 93 planned · United States
Ahead
- Nov 17, 2028Primary completion: phase 1 study in Diabetic Macular EdemaNCT07425522
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07425522Diabetic Macular Edema · United States | 1 | Recruiting | Nov 17, 2028 | 93 |
How it is read
Names in the registry
- “RO7823653”, 1 entry
Codes read as this program: RO7823653.
Conditions, from the studies’ own filings
- Macular Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.